Description
CH-221391 (CAS 301326-22-7) is an arylhydrocarbon (AhR) receptor antagonist, IC50=30 nM.1 Blocks endogenous AhR agonist-induced differentiation of Th17 cells.2?? Promotes expansion of human hematopoietic stem cells.3 Mitigates cytokine-mediated inflammatory signaling in human fibroblast-like synoviocytes.4 An important tool for probing the involvement of AhR in the toxicity of various environmental toxins such as TCDD and other dioxins.5
Biochem/physiol Actions
CH-223191 is a potent and specific aryl hydrocarbon receptor (AhR) antagonist. It inhibited TCDD-mediated nuclear translocation and DNA binding of AhR, and inhibited TCDD-induced luciferase activity with an IC50 of 30nM. Unlike some other AhR antagonists which display agonist activity at high concentrations, CH-223191 did not stimulate AhR-dependent transcription even at 100 micromolar. It is also specific for AhR, displaying no affinity for the estrogen receptor, as some other antagonists do.
References
1) Kim et al. (2006), Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor; Mol. Pharmacol., 69 1871
2) Veldhoen et al. (2009), Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells; J. Exp. Med., 206 43
3) Carlin et al. (2013), T-cell potential of human adult and cord blood hemopoietic stem cells expanded with the use of aryl hydrocarbon receptor antagonists; Cytotherapy, 15 224
4) Lahoti et al. (2013), Aryl hydrocarbon receptor antagonism mitigates cytokine-mediated inflammatory signaling in primary human fibroblast-like synoviocytes; Ann. Rheum. Dis, 72 1708
5) Petroff et al. (2011), The aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) alters early embryonic development in a rat IVF exposure model; Reprod. Toxicol., 32 286